Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice

Endocrinology

Volumn 140, Issue 11, 1999, Pages 5348-5355

  Asa, Sylvia L ^a   Kelly, Michele A ^b   Grandy, David K ^b   Low, Malcolm J ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERPLASIA; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033303537     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.11.7118     Document Type: Article

References (50)

1. The cytogenesis and pathogenesis of pituitary adenomas
2. Morphological evidence for the presence of arteries in human prolactinomas
3. Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis
4. Die Morphologie der paraadenomatosen Adenohypophyse. Ein Beitrag zur Pathogenese der Hypophysenadenome
5. Pituitary hyperplasia. Definition, light and electron microscopical structures and significance in surgical specimens
6. Dual action of dopamine on growth hormone release in vitro
7. Involvement of dopamine D1 receptors in the control of growth hormone secretion in the rat
8. Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perfusion system
9. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly
10. Differential transduction of dopamine signal in different subtypes of human growth hormone-secreting adenomas
11. Nerve growth factor directs differentiation of the bipotential cell line GH-3 into the mammotroph phenotype
12. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice
13. Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations
14. Pituitary adenomas in mice transgenic for growth hormone-releasing hormone
15. Morphologic effects of hGRH gene expression on the pituitary, liver, and pancreas of MT-hGRH transgenic mice. An in situ hybridization analysis
16. Pathogenesis of pituitary tumors
17. Prolactin-releasing factor: Cellular origin in the intermediate lobe of the pituitary
18. A prolactin-releasing peptide in the brain
19. The pituitary gland in pregnancy: A clinicopathologic and immunohistochemical study of 69 cases
20. The pathophysiology of pituitaries and their tumors: Methodologic advances
21. Galanin regulates prolactin release and lactotroph proliferation
22. Prolactinomas
23. Diagnosis and management of prolactinomas
24. Dopamine the dopamine D2 receptor and pituitary tumours
25. Demonstration of specific dopamine receptors on human pituitary adenomas
26. The D2 receptor of anterior pituitary is functionally associated with a pertussis toxin-sensitive guanine nucleotide binding protein
27. Resistance to bromocriptine in prolactinomas
28. Studies of two thyrotrophin-secreting pituitary adenomas: Evidence for dopamine receptor deficiency
29. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors
30. Prolactin release, oestrogens and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats
31. Influence of lactotroph cell density on prolactin secretion in rats
32. Effect of estrogen and neuroleptics on prolactin secretion and immunoreactive prolactin cells
33. Cabergoline in the treatment of acromegaly: A study in 64 patients
34. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine
35. The TSH secretion in the human pituitary adenomas
36. Follicle-stimulating hormone- and α-subunit-secreting pituitary tumor treated with bromocriptine
37. Dopaminergic regulation of α-subunit secretion and messenger ribonucleic acid levels in α-secreting pituitary tumors
38. The effects of bromocriptine, thyrotropin-releasing hormone, and gonadotropin-releasing hormone on hormone secretion by gonadotropin-secreting pituitary adenomas in vivo and in vitro
39. Pathogenesis of endocrine tumors
40. The role of hormones in the etiology of human breast cancer
41. Risk factors in endometrial carcinoma with special reference to the use of estrogens
42. New methods of endocrine management in prostatic cancer
43. The aetiology of thyroid tumours
44. Testicular tumors associated with congenital adrenal hyperplasia: A continuing diagnostic and therapeutic dilemma
45. Sertoli cell adenomas in patients with testicular feminization
46. Histological changes in parathyroid glands in subclinical and clinical renal disease. An autopsy investigation
47. Chemical carcinogenesis
48. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas